Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.

Butler J, Handelsman Y, Bakris G, Verma S.

Eur J Heart Fail. 2020 Jan 11. doi: 10.1002/ejhf.1708. [Epub ahead of print] Review.

PMID:
31926059
2.

Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.

Handelsman Y, Muskiet MHA, Meneilly GS.

Adv Ther. 2019 Dec 23. doi: 10.1007/s12325-019-01185-0. [Epub ahead of print]

PMID:
31873867
3.

Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication.

Bloomgarden Z, Handelsman Y.

J Diabetes. 2020 Jan;12(1):8-9. doi: 10.1111/1753-0407.13005. Epub 2019 Nov 13. No abstract available.

PMID:
31722441
4.

Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.

Handelsman Y, Muskiet MHA, Meneilly GS.

Adv Ther. 2019 Dec;36(12):3321-3339. doi: 10.1007/s12325-019-01126-x. Epub 2019 Oct 23. Review. Erratum in: Adv Ther. 2019 Dec 23;:.

5.

Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.

Handelsman Y.

Adv Ther. 2019 Oct;36(10):2567-2586. doi: 10.1007/s12325-019-01054-w. Epub 2019 Aug 23. Review.

6.

Divergence in perceptions of diabetes control among patients with type 2 diabetes mellitus treated with basal insulin and health care professionals: results from the US Perceptions of Control (POC-US) study.

Tomaszewski KJ, Allen A, Mocarski M, Schiffman A, Kruger D, Handelsman Y, Heile M, Brod M.

Patient Prefer Adherence. 2019 May 10;13:761-773. doi: 10.2147/PPA.S194598. eCollection 2019.

7.

Introduction to the 2nd Heart in Diabetes (HiD) Meeting.

Handelsman Y, Bloomgarden Z.

J Diabetes. 2019 Jul;11(7):599-600. doi: 10.1111/1753-0407.12925. Epub 2019 May 7. No abstract available.

PMID:
31066171
8.

Gerald Reaven: A man for our times.

Handelsman Y.

Diab Vasc Dis Res. 2019 Mar;16(2):113-115. doi: 10.1177/1479164119827769. No abstract available.

PMID:
31014094
9.

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study.

Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML, Elliott-Davey M, Somaratne R, Reaven P.

Diabetologia. 2019 Jun;62(6):948-958. doi: 10.1007/s00125-019-4856-7. Epub 2019 Apr 5.

10.

Corrections.

Handelsman Y, Wyne K, Cannon A, Shannon M, Schneider D.

J Manag Care Spec Pharm. 2018 Nov;24(11):1196a. doi: 10.18553/jmcp.2018.24.11.1196a. No abstract available.

11.

DYSGLYCEMIA-BASED CHRONIC DISEASE: AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS POSITION STATEMENT.

Mechanick JI, Garber AJ, Grunberger G, Handelsman Y, Garvey WT.

Endocr Pract. 2018 Nov;24(11):995-1011. doi: 10.4158/PS-2018-0139.

PMID:
30763128
12.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE.

Endocr Pract. 2019 Jan;25(1):69-100. doi: 10.4158/CS-2018-0535. Erratum in: Endocr Pract. 2019 Feb;25(2):204.

PMID:
30742570
13.

Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population.

Li S, Peng Y, Wang X, Qian Y, Xiang P, Wade SW, Guo H, Lopez JAG, Herzog CA, Handelsman Y.

Clin Cardiol. 2019 Mar;42(3):391-399. doi: 10.1002/clc.23160. Epub 2019 Feb 25.

14.

Fournier's gangrene and sodium-glucose cotransporter 2 inhibitors: Is there a causal association?

Bloomgarden Z, Einhorn D, Grunberger G, Handelsman Y.

J Diabetes. 2019 May;11(5):340-341. doi: 10.1111/1753-0407.12897. Epub 2019 Feb 3. No abstract available.

PMID:
30600643
15.

Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.

Handelsman Y, Chovanes C, Dex T, Giorgino F, Skolnik N, Souhami E, Stager W, Niemoeller E, Frias JP.

J Diabetes Complications. 2019 Mar;33(3):236-242. doi: 10.1016/j.jdiacomp.2018.11.009. Epub 2018 Nov 30.

16.

Notes from the world congress on insulin resistance, diabetes, and cardiovascular disease.

Bloomgarden Z, Handelsman Y.

J Diabetes. 2019 Apr;11(4):258-260. doi: 10.1111/1753-0407.12888. Epub 2019 Jan 3. No abstract available.

PMID:
30561080
17.

Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.

Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J.

Diabetes Obes Metab. 2018 Nov 30. doi: 10.1111/dom.13594. [Epub ahead of print]

18.

EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.

Lingvay I, Handelsman Y, Linjawi S, Vilsbøll T, Halladin N, Ranc K, Liebl A.

Endocr Pract. 2019 Feb;25(2):144-155. doi: 10.4158/EP-2018-0284. Epub 2018 Nov 1.

PMID:
30383495
19.

Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus.

Billings LK, Handelsman Y, Heile M, Schneider D, Wyne K.

J Manag Care Spec Pharm. 2018 Sep;24(9-a Suppl):S30-S41. doi: 10.18553/jmcp.2018.24.9-a.s30. Review.

20.

Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications.

Heile M, Wyne K, Billings LK, Cannon A, Handelsman Y, Shannon M.

J Manag Care Spec Pharm. 2018 Sep;24(9-a Suppl):S42-S52. doi: 10.18553/jmcp.2018.24.9-a.s42. Review.

21.

Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists.

Handelsman Y, Wyne K, Cannon A, Shannon M, Schneider D.

J Manag Care Spec Pharm. 2018 Sep;24(9-a Suppl):S14-S29. doi: 10.18553/jmcp.2018.24.9-a.s14. Review. Erratum in: J Manag Care Spec Pharm. 2018 Nov;24(11):1196a.

22.

Burden of Illness in Type 2 Diabetes Mellitus.

Cannon A, Handelsman Y, Heile M, Shannon M.

J Manag Care Spec Pharm. 2018 Sep;24(9-a Suppl):S5-S13. doi: 10.18553/jmcp.2018.24.9-a.s5. Review.

23.

Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.

Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, Perfetti R, Meier JJ.

Diabetes Obes Metab. 2018 Dec;20(12):2821-2829. doi: 10.1111/dom.13462. Epub 2018 Aug 13.

24.

World congress on insulin resistance, diabetes and cardiovascular disease.

Bloomgarden Z, Handelsman Y.

J Diabetes. 2018 Oct;10(10):776-777. doi: 10.1111/1753-0407.12787. Epub 2018 Jul 4. No abstract available.

PMID:
29971929
25.

PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review.

Handelsman Y, Lepor NE.

J Am Heart Assoc. 2018 Jun 22;7(13). pii: e008953. doi: 10.1161/JAHA.118.008953. Review. No abstract available.

26.

American College of Physicians diabetes guidelines attempt to turn back the clock, conflating good HbA1c with hypoglycemia.

Bloomgarden Z, Einhorn D, Handelsman Y, Misra A, Zonszein J, Grunberger G, Jellinger PS, Garber AJ.

J Diabetes. 2018 Aug;10(8):618-620. doi: 10.1111/1753-0407.12668. Epub 2018 May 4. No abstract available.

PMID:
29655268
27.

Transition from hospital to outpatient diabetes care.

Bloomgarden Z, Handelsman Y.

J Diabetes. 2018 Jul;10(7):538-540. doi: 10.1111/1753-0407.12664. Epub 2018 Apr 17. No abstract available.

PMID:
29655199
28.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2018 POSITION STATEMENT ON INTEGRATION OF INSULIN PUMPS AND CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH DIABETES MELLITUS.

Grunberger G, Handelsman Y, Bloomgarden ZT, Fonseca VA, Garber AJ, Haas RA, Roberts VL, Umpierrez GE.

Endocr Pract. 2018 Mar;24(3):302-308. doi: 10.4158/PS-2017-0155.

PMID:
29547046
29.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE.

Endocr Pract. 2018 Jan;24(1):91-120. doi: 10.4158/CS-2017-0153. Epub 2018 Jan 17.

PMID:
29368965
30.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON TESTING FOR AUTONOMIC AND SOMATIC NERVE DYSFUNCTION.

Vinik AI, Camacho PM, Davidson JA, Handelsman Y, Lando HM, Leddy AL, Reddy SK, Cook R, Spallone V, Tesfaye S, Ziegler D; Task Force to Develop an AACE Position Statement on Autonomic Testing.

Endocr Pract. 2017 Dec;23(12):1472-1478. doi: 10.4158/EP-2017-0053.

PMID:
29320641
31.

AACE/ACE POSITION STATEMENT ON THE USE OF FOLLOW-ON BIOLOGICS AND BIOSIMILARS FOR ENDOCRINE DISEASES.

Fonseca VA, Bloomgarden ZT, Dagogo-Jack S, Grunberger G, Einhorn D, Garber AJ, Handelsman Y, Hirsch IB, Umpierrez GE.

Endocr Pract. 2017 Nov;23(11):1345-1349. doi: 10.4158/EP-2017-0052.

PMID:
29190135
32.

How does CKD affect HbA1c?

Bloomgarden Z, Handelsman Y.

J Diabetes. 2018 Apr;10(4):270. doi: 10.1111/1753-0407.12624. Epub 2017 Dec 21.

PMID:
29124865
33.

Response to Comment on Bloomgarden et al. Is HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old? Diabetes Care 2017;40:526-528.

Bloomgarden ZT, Einhorn D, Handelsman Y.

Diabetes Care. 2017 Oct;40(10):e154. doi: 10.2337/dci17-0027. No abstract available.

PMID:
28931711
34.

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR.

Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-950. doi: 10.1016/S2213-8587(17)30313-3. Epub 2017 Sep 15.

35.

Concomitant Diabetes and Atrial Fibrillation: No Sugarcoating the Bittersweet Reality.

Bloomgarden ZT, Kosiborod MN, Handelsman Y.

J Am Coll Cardiol. 2017 Sep 12;70(11):1336-1338. doi: 10.1016/j.jacc.2017.07.773. No abstract available.

36.

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.

Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, Kvist K, Norwood P.

JAMA. 2017 Jul 4;318(1):45-56. doi: 10.1001/jama.2017.7117.

37.

JCL roundtable: Future of the lipid laboratory: Using the laboratory to manage the patient (part 2).

Brown WV, Handelsman Y, Martin SS, Morris PB.

J Clin Lipidol. 2017 Jul - Aug;11(4):846-854. doi: 10.1016/j.jacl.2017.05.002. Epub 2017 May 25. Review.

PMID:
28642100
38.

A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Handelsman Y, Lauring B, Gantz I, Iredale C, O'Neill EA, Wei Z, Suryawanshi S, Kaufman KD, Engel SS, Lai E.

Curr Med Res Opin. 2017 Oct;33(10):1861-1868. doi: 10.1080/03007995.2017.1335638. Epub 2017 Jun 28.

PMID:
28548024
39.

JCL roundtable: Future of the lipid laboratory: Choosing valuable measures among the lipoproteins (part 1).

Brown WV, Handelsman Y, Martin SS, Morris PB.

J Clin Lipidol. 2017 May - Jun;11(3):587-595. doi: 10.1016/j.jacl.2017.04.113. Epub 2017 Apr 21.

PMID:
28465133
40.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.

Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M.

Endocr Pract. 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL.

PMID:
28437620
41.

Is HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old?

Bloomgarden ZT, Einhorn D, Handelsman Y.

Diabetes Care. 2017 Apr;40(4):526-528. doi: 10.2337/dci16-0043. No abstract available.

PMID:
28325800
42.

Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II.

Leiter LA, Zamorano JL, Bujas-Bobanovic M, Louie MJ, Lecorps G, Cannon CP, Handelsman Y.

Diabetes Obes Metab. 2017 Jul;19(7):989-996. doi: 10.1111/dom.12909. Epub 2017 Apr 18.

43.

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com.

Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M, Zangeneh F, Bush MA.

Endocr Pract. 2017 Apr 2;23(4):479-497. doi: 10.4158/EP171764.GL. Epub 2017 Feb 3.

PMID:
28156151
44.

Diabetes treatment over age 65: Is worse control really better?

Bloomgarden Z, Mende C, Einhorn D, Handelsman Y.

J Diabetes. 2017 May;9(5):428-430. doi: 10.1111/1753-0407.12535. Epub 2017 Feb 28. No abstract available.

PMID:
28133929
45.

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.

Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, DeFronzo RA, Einhorn D, Fonseca VA, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez GE.

Endocr Pract. 2017 Feb;23(2):207-238. doi: 10.4158/EP161682.CS. Epub 2017 Jan 17.

PMID:
28095040
46.

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.

Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop PH, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JP, Ratner RE.

Diabetes. 2017 Feb;66(2):241-255. doi: 10.2337/db16-0806. Epub 2016 Dec 15. Review.

47.

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.

Linjawi S, Bode BW, Chaykin LB, Courrèges JP, Handelsman Y, Lehmann LM, Mishra A, Simpson RW.

Diabetes Ther. 2017 Feb;8(1):101-114. doi: 10.1007/s13300-016-0218-3. Epub 2016 Dec 10.

48.

TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.

Handelsman Y, Shapiro MD.

Endocr Pract. 2017 Jan;23(1):100-112. doi: 10.4158/EP161445.RA. Epub 2016 Nov 7. Review.

PMID:
27819772
49.

Cardiac Manifestations of Congenital Generalized Lipodystrophy.

Sanon VP, Handelsman Y, Pham SV, Chilton R.

Clin Diabetes. 2016 Oct;34(4):181-186.

50.

Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with ≥5% weight loss.

Handelsman Y, Fain R, Wang Z, Li X, Fujioka K, Shanahan W.

Postgrad Med. 2016 Nov;128(8):740-746. Epub 2016 Oct 19.

PMID:
27659698

Supplemental Content

Loading ...
Support Center